CBC Group

Hunan Yiyi Pharmaceutical Technology develops and operates an online platform for pharmaceutical products. It allows members to purchase various medicines. Hunan Yiyi Pharmaceutical Technology was founded in 2019 and is based in Jiangsu, China.

Axbio Inc. is a biotechnology company based in Shenzhen, China, specializing in genetic sequencing technology and diagnostic solutions. Founded in 2016, the company develops a variety of products, including genome extraction kits for stool, blood, saliva, and bacteria. Axbio also provides advanced sequencing systems, disposable biochips, and reagents. The company is focused on creating high-throughput molecular diagnostics through its novel microfluidic Bio-CMOS platform, which supports both low-cost handheld devices for bedside diagnostics and fully automated laboratory instruments. This technology enables applications such as early cancer screening, rapid pathogen detection, and drug development. Currently, Axbio operates in stealth mode as it continues to innovate within the field.

InxMed is a clinical-stage biotechnology company dedicated to developing innovative cancer therapeutics aimed at improving treatment outcomes for patients. The company focuses on creating "Best-in-Disease Combination" medicines, which are designed to target various forms of cancer, including pancreatic, ovarian, and gastric cancers. InxMed's approach is grounded in a thorough understanding of disease biology and pharmacology, allowing for the development of novel treatment options. The company is committed to establishing a robust translational platform that combines advanced expertise with efficient execution capabilities to enhance the effectiveness of cancer therapies available to healthcare professionals and their patients.

ENSEM Therapeutics is an innovative drug discovery and development company focused on creating precision medicines for oncology. Utilizing its Kinetic Ensemble platform, the company aims to discover and develop transformative small-molecule therapies that address complex drug targets associated with cancer. By integrating advanced technologies, ENSEM Therapeutics can detect and characterize rare conformational states in drug targets, which are crucial for understanding oncogenic processes, regulatory mechanisms, and drug resistance. This approach opens new avenues for therapeutic intervention, allowing drug developers to target high-value and challenging areas within oncology while also considering potential applications in genetic disorders and other diseases.

Trevena, Inc. is a biopharmaceutical company based in Chesterbrook, Pennsylvania, established in 2007. The company is dedicated to the development and commercialization of innovative medicines aimed at treating central nervous system disorders. Its product candidates include Oliceridine injection, which is designed for managing moderate-to-severe acute pain and has completed Phase III clinical trials, and TRV250, a delta-opioid receptor agonist that has finished Phase I trials for acute migraine treatment. Other candidates in development include TRV734, targeting both acute and chronic pain, and TRV027, which is being evaluated for acute heart failure. Additionally, Trevena is collaborating with Imperial College London to study TRV027 in the context of COVID-19. The company employs a specialized approach using G protein biased ligands to enhance the efficacy and safety of its therapeutics, addressing the limitations of existing GPCR-targeted drugs.

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Boston, Massachusetts, specializing in the development and commercialization of innovative therapies derived from novel tetracycline chemistry. The company’s lead product, NUZYRA, is a broad-spectrum antibiotic administered in both oral and intravenous forms, targeting adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Another significant product, SEYSARA, is designed for the treatment of moderate to severe acne vulgaris. Paratek has received Qualified Infectious Disease Product designation from the U.S. Food and Drug Administration for its lead antibiotic, reflecting its commitment to addressing urgent public health threats, including antibiotic resistance. The company maintains various collaboration agreements, including partnerships with Zai Lab and Allergan, as well as research agreements with academic institutions and military organizations, to further its mission in combating infectious diseases and exploring additional therapeutic areas such as multiple sclerosis and systemic inflammatory diseases.

ABio-X is a biotechnology holding company headquartered in Waltham, Massachusetts, dedicated to incubating organizations that merge innovative science with advanced technologies. Its primary focus is on developing transformative medicines and solutions aimed at addressing global health challenges. Each incubated company operates with its own product portfolio and leadership team while benefiting from a centralized shared services environment, which enhances operational efficiency and fosters innovation. Through this model, ABio-X aims to drive significant advancements in the biotechnology sector and improve patient outcomes worldwide.

Jadeite Medicines is a biopharmaceutical company dedicated to developing and commercializing innovative pharmaceutical products. The company aims to address unmet clinical needs by creating novel medicines that enhance treatment options for patients. Through its focus on research and development, Jadeite Medicines strives to improve the quality of healthcare by providing effective solutions in the biopharmaceutical sector.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.

Lu Daopei Medical Group is a prominent healthcare provider based in Beijing, China, specializing in hematology and bone marrow transplantation. Founded in 2002, the group operates a network of hospitals that offer a range of services, including departments focused on bone marrow transplantation, general hematology, lymphoma and myeloma treatment, as well as pathology and specialty hematology laboratories. The organization is recognized for its expertise in stem cell transplantation and oncology, providing comprehensive clinical diagnosis and treatment options. Lu Daopei Medical Group aims to assist patients in navigating the complexities of their medical care, ultimately reducing their anxiety and improving treatment outcomes.